Regulatory Affairs and Clinical Use of EV-based Therapeutics Task ForceAboutThe TF is composed of global experts whose experience spans academia, clinical development, industry, and regulatory affairs in the EV research and therapy field. The Task Force is focusing on the discovery of EV-based therapeutic strategies and their clinical translation. The identification of the relevant regulatory guidance and their application to EVs as investigational new drugs (INDs) in clinical studies is a major goal as well as to support safe and effective EV-based treatment concepts worldwide. Working GroupsTwo subgroups should facilitate bench-to-bedside transfer by 1) identifying analytical tools for potency measurement of EV’s safety and efficacy and 2) define reporting standards that relate to the modification of EVs to enhance therapeutic potency or improve and monitor biodistribution, targeting and cellular uptake. In a long-term perspective, these subgroups “Biological standardisation and development of international potency standards for EVs” and “Reporting Standards for Modified Extracellular Vesicles” are focusing on the acceleration of translational research and clinical evaluation of EV-based therapeutics. Chair Contact InfoMembersBenedetta Bussolati | Edit Buzas | Rachel Ciccocioppo | Owen Davies | Juan M. Falcon-Perez | Qing-Ling Fu | Bernd Giebel | Mario Gimona | Rebecca Lim | Sai Kiang Lim | Lorraine O'Driscoll | Xenia Sango | Ralf Sanzenbacher | Hidetoshi Tahara | Clotilde Thery | Wei Seong Toh | Marca Wauben | Daniel Weiss | Kenneth Witwer | Sun Young Lee | Pascale Zimmermann Publications
Other Outputs
View All Task Forces |